1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,260 | 2,490 | 22:30 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | XSpray Pharma AB: Xspray Pharma provides update on the FDA process for Dasynoc - observations at contract manufacturer delay approval | 131 | GlobeNewswire (Europe) | • FDA has issued a Complete Response Letter (CRL) regarding Xspray Pharma's New Drug Application (NDA) for Dasynoc, referring to GMP (Good Manufacturing Practice) observations at a contract manufacturer.... ► Artikel lesen | |
| 11.09. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue increased and fully utilized | 180 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 26.08. | Listing of subscription rights and paid subscription shares of XSpray Pharma AB | 286 | GlobeNewswire | With effect from August 27, 2025, the subscription rights of XSpray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including September 04, 2025.
Instrument:
Subscription... ► Artikel lesen | |
| 25.08. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 277 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA... ► Artikel lesen | |
| 21.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 21.08.2025 | 317 | Xetra Newsboard | Das Instrument 6O1 CA13810W1023 CANTER RESOURCES CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 21.08.2025 und ex Kapitalmassnahme am 22.08.2025 The instrument 6O1 CA13810W1023 CANTER RESOURCES... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.08. | XSpray Pharma AB: Xspray Pharma Submits XS003 to the FDA - The Company's Second Product Candidate from the HyNap Platform | 390 | GlobeNewswire (Europe) | Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic... ► Artikel lesen | |
| 15.08. | XSpray Pharma AB: Interim Report Second Quarter 2025 | 155 | GlobeNewswire (Europe) | April-June 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -44,885 thousand (-53,620)Earnings per share before dilution amounted to SEK -2.35 (-1.64)Cash flow... ► Artikel lesen | |
| 12.08. | Xspray Pharma Signs License Agreement With Handa Therapeutics For Dasatinib Product | 1 | RTTNews | ||
| 12.08. | XSpray Pharma AB: Xspray Pharma signs license agreement with Handa Therapeutics - to receive up to double-digit royalty on Handa's net proceeds | 193 | GlobeNewswire (Europe) | Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization... ► Artikel lesen | |
| 11.07. | XSpray Pharma AB: XSpray Pharma achieves significant milestone - demonstrating bioequivalence with absorption advantages compared to Tasigna | 155 | GlobeNewswire (Europe) | Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate... ► Artikel lesen | |
| 27.06. | XSpray Pharma AB: Xspray Pharma Passes FDA Pre-Approval Inspection - Key Regulatory Milestone Achieved for Dasynoc | 439 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has conducted a successful Pre-Approval Inspection (PAI) of the company's manufacturing lines, located at a contract... ► Artikel lesen | |
| 14.05. | XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc | 327 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)... ► Artikel lesen | |
| 13.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) | 125 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025.
Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 07.05. | XSpray Pharma AB: Interim Report First Quarter 2025 | 177 | GlobeNewswire (Europe) | January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•... ► Artikel lesen | |
| 08.04. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application | 258 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 130 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen | |
| 20.01. | XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025 | 160 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology... ► Artikel lesen | |
| 14.11.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB | 384 | GlobeNewswire | With effect from November 15, 2024, the subscription rights of Xspray Pharma
AB will be traded on the list for Equity rights. Trading will continue up until
and including November 26, 2024.
Instrument:... ► Artikel lesen | |
| 12.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.2024 | 2.745 | Xetra Newsboard | Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Interim Report Third Quarter 2024 | 203 | GlobeNewswire (Europe) | July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 42,065 | -0,10 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 5,500 | -3,51 % | Sana Biotech surges as Eric Jackson calls it a 100-bagger | ||
| ARCTURUS THERAPEUTICS | 11,600 | -49,89 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,415 | -16,15 % | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,745 | -5,97 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| BICARA THERAPEUTICS | 16,450 | -3,35 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L HPV-Negative R/M HNSCC | BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen | |
| EVOTEC | 6,726 | -1,41 % | Übernahme von Vidac Pharma und Evotec? 400 Mrd. USD bei Pfizer, Merck und Co im Feuer! | Alarm bei Big Pharma! Donald Trump scheint bei der Reduzierung von Medikamentenpreisen ernst zu machen. Gleichzeitig laufen Patente bei Blockbustern aus und ein 400 Mrd. USD Umsatzausfall droht. Pfizer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,140 | +1,92 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| NURIX THERAPEUTICS | 10,640 | +2,01 % | Nurix Therapeutics, Inc.: Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia | 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated... ► Artikel lesen | |
| LENZ THERAPEUTICS | 32,690 | -2,45 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| BIONTECH | 91,50 | -0,81 % | Übernahmefieber und KI-Chance: BioNTech, Novo Nordisk, PanGenomic Health Aktie | Übernahmefieber im Pharma- und Biotech-Bereich. Novo Nordisk hat nach der angekündigten Milliardenübernahme in den USA den nächsten Deal gemeldet. Die Dänen sehen ein mögliches Best-in-Class-Therapeutikum... ► Artikel lesen | |
| COGENT BIOSCIENCES | 14,830 | -6,49 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen | |
| DISC MEDICINE | 87,20 | +1,22 % | Disc Medicine Inc: Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,670 | -7,43 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 10,520 | -6,41 % | 4D Molecular Therapeutics stock maintains Outperform rating at RBC Capital |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,050 (+2,19 %) liegt der Kurs bei 2,335 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.